RSS   Newsletter   Contact   Advertise with us
Post Online Media

Nouscom names new COO, strengthens board

NouscomNouscom, an oncology company, announced the appointment of Marina Udier Blagovic as chief operating officer, the new position.
Article continues below

READ MORE Petrobras names new investor relations executive manager

Dr. Udier Blagovic joins Nouscom from Versant Ventures where she was an Operating Principal.

Prior to Versant, she was the Global Head of Neurodegeneration at Novartis where she managed blockbuster brands. Her experience in oncology includes the development of a companion diagnostics.

Prior to that, Dr. Udier Blagovic worked in the healthcare sector of McKinsey & Company in Chicago.

She has a Ph.D. in Organic Chemistry from Yale University.

The Company also announces that Jean-Paul Prieels will join the board as Non-Executive Director.

Dr. Prieels served as a Senior Vice President of Research and Development at GSK Biologicals (now GSK Vaccines) until January 2011.

Dr. Prieels joined GSK Biologicals in 1987 and progressed in roles of increasing responsibility to eventually lead the global vaccine R&D development activities in Rixensart, Belgium.

He was instrumental in developing several commercially available vaccines, such as rotavirus, human papilloma virus (HPV) and pneumococcal conjugates. He serves as a Director of Vaximm AG and is on the independent Advisory Board of Curevac.

Since 2007, Dr. Prieels also has been a Member of the Scientific Advisory Board of the Singapore Bioprocessing Technology Institute.

Vincent Brichard and Gianni Gromo will join as Board Observers.

Dr. Brichard has more than 25 years’ experience in oncology and immunology, including 15 years at GSK where he was Senior Vice-President in R&D responsible for the Immunotherapeutics Business Unit and was a member of the Board of Directors at GSK Biologicals.

Dr. Brichard, a physician by training, holds a Ph.D. in tumor immunology and has authored more than 100 publications in peer-reviewed journals.

He currently serves on several Scientific Councils and Boards of Directors. He also holds an executive MBA from Harvard Business School.

Dr. Gromo is a Partner with Versant Ventures, and a former Senior Executive with several pharmaceutical companies, most recently Hoffmann-La Roche, where he was the Research Head of Global Cardiovascular and Metabolic Research and the Head of the Roche China R&D center in Shanghai.

Prior to Roche, Dr. Gromo was an Assistant Professor at the University of Minnesota; Research Director at Italfarmaco SpA, Milano, Italy; and Director of Biology-Cardiovascular at Lilly Research Laboratories.

He serves as a Scientific Advisor to multiple companies and University Boards in Europe, North America, Australia and the Middle East.

Dr. Gromo received his M.D. and Ph.D. in Clinical and Experimental Hematology at the University of Milano, Italy.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy